Sonoma Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Sonoma Pharmaceuticals de 43.7% y 24.4% respectivamente, mientras que el BPA crecerá en un 58.5% al año.

Información clave

43.7%

Tasa de crecimiento de los beneficios

58.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	22.8%
Tasa de crecimiento de los ingresos	24.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	25 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:SNOA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2026	22	-1	N/A	1	1
3/31/2025	18	-4	N/A	-2	1
3/31/2024	15	-5	N/A	-4	1
12/31/2023	12	-5	-5	-5	N/A
9/30/2023	12	-6	-4	-4	N/A
6/30/2023	13	-6	-5	-5	N/A
3/31/2023	13	-5	-6	-6	N/A
12/31/2022	13	-7	-5	-5	N/A
9/30/2022	13	-6	-5	-5	N/A
6/30/2022	13	-5	-5	-5	N/A
3/31/2022	13	-5	-4	-4	N/A
12/31/2021	12	-6	-4	-4	N/A
9/30/2021	15	-5	-3	-3	N/A
6/30/2021	17	-5	-2	-2	N/A
3/31/2021	19	-5	-4	-3	N/A
12/31/2020	21	-3	-6	-5	N/A
9/30/2020	20	-4	-7	-7	N/A
6/30/2020	19	-5	-8	-8	N/A
3/31/2020	18	-4	-5	-5	N/A
12/31/2019	18	-5	-4	-4	N/A
9/30/2019	19	-6	-5	-5	N/A
6/30/2019	19	-8	-8	-8	N/A
3/31/2019	19	-12	-12	-12	N/A
12/31/2018	18	-13	-12	-12	N/A
9/30/2018	18	-14	-12	-12	N/A
6/30/2018	17	-14	-11	-11	N/A
3/31/2018	17	-14	-13	-12	N/A
12/31/2017	17	-12	-12	-12	N/A
9/30/2017	16	-9	N/A	-11	N/A
6/30/2017	14	-9	N/A	-10	N/A
3/31/2017	13	-9	N/A	-8	N/A
12/31/2016	11	-9	N/A	-7	N/A
9/30/2016	10	-14	N/A	-8	N/A
6/30/2016	8	-16	N/A	-9	N/A
3/31/2016	9	-15	N/A	-9	N/A
12/31/2015	11	-13	N/A	-10	N/A
9/30/2015	12	-14	N/A	-8	N/A
6/30/2015	14	-10	N/A	-8	N/A
3/31/2015	14	-8	N/A	-7	N/A
12/31/2014	13	1	N/A	-6	N/A
9/30/2014	13	6	N/A	-5	N/A
6/30/2014	14	5	N/A	-5	N/A
3/31/2014	14	4	N/A	-5	N/A
12/31/2013	14	-6	N/A	-4	N/A
9/30/2013	14	-7	N/A	-5	N/A
6/30/2013	15	-8	N/A	1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que SNOA siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que SNOA siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que SNOA siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (24.4% al año) de SNOA crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (24.4% al año) de SNOA crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SNOA se prevé que sea elevada dentro de 3 años.

Sonoma Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

No longer forecast to breakeven

Recent updates

Nasdaq Grants Extension to Sonoma Pharmaceuticals to Regain Minimum Bid Price Requirement

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.785679 million.

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.392077 million.

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

New minor risk - Share price stability

Sonoma Pharmaceuticals Receives Letter from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price for its Common Stock

No longer forecast to breakeven

New major risk - Share price stability

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.29 loss in 1Q 2023)

Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller

Full year 2023 earnings released: US$1.52 loss per share (vs US$1.92 loss in FY 2022)

Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

Third quarter 2023 earnings released: US$0.62 loss per share (vs US$0.31 loss in 3Q 2022)

Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas

Second quarter 2023 earnings released: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)

Sonoma Pharmaceuticals, Inc. Launches Two New Dermatological Products

Sonoma Pharmaceuticals, Inc. Announces CFO Changes

Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M

Sonoma Pharmaceuticals, Inc. Announces Resignation of Jerry Dvonch as Chief Financial Officer

Sonoma Pharmaceuticals, Inc. Announces Close of Office in Woodstock, Georgia Effective on or Before December 31, 2022

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Sonoma Pharmaceuticals, Inc. and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S

Insufficient new directors

Sonoma Pharmaceuticals, Inc. Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2022 earnings released: US$0.033 loss per share (vs US$0.075 profit in 2Q 2021)

Insufficient new directors

Insufficient new directors

Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe

Does Sonoma Pharmaceuticals (NASDAQ:SNOA) Have A Healthy Balance Sheet?

Sonoma Pharmaceuticals Announces Expanded Dental Care Line with a New Product for Professional Care in the U.S. and a New Product for Professional and Consumer Care in Switzerland

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

New 90-day high: US$9.64

Sonoma Pharmaceuticals, Inc. and Microderm Technologies Ltd. Announce That Dermodacyn Disinfecting Solution Is Now Available in Hong Kong and Thailand

Sonoma Pharmaceuticals, Inc. Announces Partnership with Gabriel Science, LLC for Dental Markets

Sonoma Pharmaceuticals, Inc. and Crown Laboratories, Inc. Announce Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products

Sonoma Pharmaceuticals reports FQ2 results

Sonoma Pharmaceuticals, Inc. announced delayed 10-Q filing

Sonoma Pharmaceuticals and MicroSafe Group Announces that Health Canada Authorized Nanocyn® Disinfectant & Sanitizer to be Sold in Canada as a Hard-Surface Disinfectant under COVID-19 Interim Measure

Sonoma Pharmaceuticals, Inc. Plans to Relocate Remaining Manufacturing to Mexico

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento